TGFBR2 and breast cancer: Furthermore, USP8 176 and USP11 177 enhance TGF-β/SMAD signaling by deubiquitinating and stabilizing TβRII, increasing plasma membrane expression and promoting EMT, invasion, and metastasis in BC cells in vitro and in vivo.